Prothena (PRTA) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Turn Therapeutics (TTRX) has outperformed Prothena (PRTA) over the past year, gaining 72.9% versus a loss of 16.6%. Prothena is the larger company by market cap ($435.3 million vs $367.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRTA | TTRX |
|---|---|---|
| Share price | $8.48 | $12.10 |
| Market cap | $435.34M | $367.45M |
| 1-day change | +5.74% | +3.95% |
| YTD return | -11.20% | +207.11% |
| 1-year return | -16.62% | +72.86% |
| 5-year return | -86.64% | — |
| EPS (TTM) | $-0.82 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.80 | $26.50 |
| 52-week low | $7.73 | $2.57 |
| Distance from 52-week high | -28.14% | -54.34% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +152.36% | +106.61% |
| Average volume | 478.70K | 114.62K |
| Shares outstanding | 51.34M | 30.37M |
| Employees | 67 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TTRX has outperformed PRTA by 89.5 percentage points over the past year.
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Healthcare · Biotechnology · 67 employees
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Healthcare · Biotechnology · 2 employees
PRTA vs TTRX FAQ
Which is bigger, Prothena or Turn Therapeutics?
Prothena (PRTA) is larger, with a market capitalization of $435.34M compared with $367.45M for Turn Therapeutics (TTRX).
Which stock has performed better over the past year, PRTA or TTRX?
TTRX returned +72.86% over the past 12 months, compared with -16.62% for PRTA (price return, excluding dividends). Past performance does not predict future results.
Are Prothena and Turn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.